Search

Displaying results 4861 - 4870 of 7897 in total
  1. Drug

    alpha-D-quinovopyranose

    go.drugbank.com/drugs/DB03773
    Experimental

    The pyranose form of D-quinovose with an α-configuration at the anomeric position .

  2. Drug

    Fostemsavir

    go.drugbank.com/drugs/DB11796
    ApprovedInvestigational

    [L14867] The discovery of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and was born out of a desire to find alternative target proteins (i.e. mechanistically … Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor.

  3. Drug

    CM4620

    go.drugbank.com/drugs/DB16466
    Investigational

    CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and...

  4. Drug

    NV-07a

    go.drugbank.com/drugs/DB05845
    Experimental

    NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.

  5. Drug

    Tazarotene

    go.drugbank.com/drugs/DB00799
    Approved

    It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage). … Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids.

  6. Drug

    KUR-113

    go.drugbank.com/drugs/DB18413
    Investigational

    KUR-113 is an investigational fibrin-based agent containing an N-terminally modified parathyroid hormone fragment. It is being investigated as a bioactive bone graft substitute.

    Synonyms: Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34
  7. Drug

    Candoxatril

    go.drugbank.com/drugs/DB00616
    Experimental

    Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.

  8. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer

  9. Drug

    Rolofylline

    go.drugbank.com/drugs/DB12670
    Investigational

    Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.

  10. Drug

    Sodium bisulfite

    go.drugbank.com/drugs/DB14015
    ApprovedWithdrawn

    Sodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.

    Categories: Compounds used in a research, industrial, or household setting